Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
NK911 is a novel supramolecular nanocarrier designed for the enhanced delivery of doxorubicin (DXR) and is one of the successful polymer micelle systems to exhibit an efficient accumulation in solid tumours in mice. The purpose of this study was to define the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of NK911 and to evaluate its pharmacokinetic profile in man. NK911 was given intravenously to patients with solid tumours every 3 weeks using an infusion pump at a rate of 10 mg DXR equivalent min(-1). The starting dose was 6 mg DXR equivalent m(-2), and the dose was escalated according to the accelerated titration method. A total of 23 patients participated in this study. Neutropenia was the predominant haematological toxicity, and grade 3 or 4 neutropenia was observed at doses of 50 and 67 mg m(-2). Common nonhaematological toxicities were mild alopecia, stomatitis, and anorexia. In the dose identification part of the study, DLTs were observed at a dose of 67 mg m(-2) (grade 4 neutropenia lasting more than 5 days). Thus, this dosage level was determined to be the MTD. Infusion-related reactions were not observed in any cases. The C(5 min) and area under the concentration curve parameters of NK911 exhibited dose-dependent characteristics. Among the 23 patients, a partial response was obtained in one patient with metastatic pancreatic cancer. NK911 was well tolerated and produced only moderate nausea and vomiting at myelosuppressive dosages. The recommended phase II dose was determined to be 50 mg m(-2) every 3 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This same concept was used by Kataoka and colleagues in a series of works leading to development of polymeric micelle NK911, which was evaluated clinically [146, 147].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“These characteristics, which are unique to solid tumours, constitute the basis of the enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986; Maeda et al, 2000).”
BackgroundSelf-citationWHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211 · cited 2×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
BackgroundMuggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.987 · Cited by 647 · cited 2×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
BackgroundAccelerated Titration Designs for Phase I Clinical Trials in Oncology
Simon, R., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 639 · cited 2×
“Dose escalation was performed according to the previously described accelerated titration method (Simon et al, 1997).”
MethodDevelopment of the polymer micelle carrier system for doxorubicin
Nakanishi, T., Fukushima, S., Okamoto, K., Suzuki, M., Matsumura, Y., Yokoyama, M., Okano, T., Sakurai, Y., & Kataoka, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00341-8 · Cited by 570 · cited 7×
“The hydrophobic inner core enables NK911 to entrap a sufficient amount of DXR. NK911 has a diameter of about 40 nm (Nakanishi et al, 2001).”
BackgroundMethodSelf-citationUziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., & Gabizon, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1777 · Cited by 477 · cited 1×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
Background(1991) · PubMed · Cited by 418
Cited by
Items 601–621 of 621
Коbylinska, L. I., Mitina, N., Zaichenko, A., & Стойка, Р. С. (2024) · Springer eBooks · doi:10.1007/978-3-031-61877-2_5
Wang, S., Xiao, S., Li, N., Xu, Y., & Song, Z. (2025) · Macromolecular Bioscience · doi:10.1002/mabi.202500063 · Cited by 1
Saraiva, N. M., Alves, A. C., Barbosa, A. I., Marinho, A., Reis, S., Correia‐da‐Silva, M., & Costa, P. C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060771
Research Progress of Ultrasound-Responsive Polymeric Microparticles in the Field of Bone Repair
袁, 小. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1561875
Nanotheranostic Approach for Cancer Treatment
Ahmad, M. Z., Pathak, K., Bhatnagar, D., Ladhe, S., Kumar, D., Saikia, R., & Das, A. (2025) · Springer eBooks · doi:10.1007/978-3-032-00773-5_296
DESIGN AND SYNTHESIS OF MULTIFUNCTIONAL POLYMERIC MICELLES FOR GENE-DIRECTED ENZYME PRODRUG THERAPY
Sawdon, A. J. (2014) · Digital Commons - Michigan Tech (Michigan Technological University) · doi:10.37099/mtu.dc.etds/862
“That is, if the HSV-TK gene is delivered to actively dividing cancer cells, and ACV is subsequently administered to the cells, the TK enzyme phosphorylates ACV, yielding toxic metabolites which cause death in prodrug treated HSV-TK expressing cells [17-19].”
BackgroundResultSelf-Microemulsifying Materials
Holowka, E. P., & Bhatia, S. K. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1998-7_4
Zhang, T., Fu, Y., Wang, M., Zhang, X., Geng, C., Lv, Z., Shi, F., & Wang, S. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5853502
Kim, T. H., Kim, W., Kim, W.-J., Park, J.-S., Park, S.-Y., Jeong, Y., Kim, H., & Kim, S.-J. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s569702 · Cited by 1
“21 Despite these advantages, however, some drawbacks of polymeric micelle systems, such as their lack of cancer cell specificity and inability to distinguish the abnormal tumor physiological conditions, remain problematic.”
Nanoparticules de resveratrol/PLAGA pour réduire la toxicité notamment hépatique de la doxorubicine
Bengaied, D. (2018) · theses.fr (ABES) · doi:10.70675/e4fb4ae8z8f4bz4102z8154z52fb69dc4af4
Costamagna, F. (2020) · theses.fr (ABES) · doi:10.70675/1dc94a37z9cefz4652z9c2cza482cbf0efc3 · Cited by 1
Theranostic of rhabdomyosarcoma with functionalized nanoparticles
Gil, S. D. (2021) · theses.fr (ABES) · doi:10.70675/59ca1119zb15cz43f4zb4fbz1102ac5443d5
Polymer-doxorubicin Conjugates: Redefining Chemotherapy for Breast Cancer
Kumari, S., Kumar, A., Islam, M. M., Singh, N., Patel, P., & Kurmi, B. D. (2026) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575471485260408204857
Patel, Y. H., Ranch, K. M., Jani, H., Patel, C. R., Jacob, S., Mohamed, M. R., & Boddu, S. H. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36453-2.00012-4
Current advances in liposome–extracellular vesicle hybrid systems for cancer drug delivery
Habibi, A., Sakhti, M., Ahmadi-Jouybari, T., Yavari, P., Mozafari, R., Rostaminasab, G., & Rahmati, S. (2026) · Clinical and Translational Discovery · doi:10.1002/ctd2.70162
Challenges and future horizons in nanomedicine
Sharma, C., Khan, A., Singh, S., Gautam, S., Potdar, P., & Scott, E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36532-4.00012-2
Polymeric micelles as versatile shuttles: Strategic approaches for glioblastoma-targeted delivery
Verma, M., Kumar, A., Kanaujiya, S., Subhashchandra, G. K., Mittal, K., & Rajinikanth, P. S. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108622
Advances in polymeric nanoparticles for anticancer drug delivery
Hirave, K. S., Morya, N., Kumar, L., Banerjee, S., Saharan, V. A., & Singh, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44185-1.00027-6
Serbun, P., Shaikenov, R. O., Snetkov, P., Kosová, A., Budanov, M., Rybalka, A. V., & Morozkina, S. N. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198704 · Cited by 1
Bhatia, S. K. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6920-0_9
Metadata
- Authors
- Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., & Watanabe, N.
- Affiliations
- National Cancer Center Hospital East (JP)
- National Cancer Center Hospital (JP)
- Nippon Kayaku (Japan) (JP)
- Corresponding author
- Matsumura, Y
- Venue
- British Journal of Cancer
- Published
- 2004-10-12
- Volume
- 91
- Issue
- 10
- Pages
- 1775-1781
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2410050
- OpenAlex
- W2056347214
- Cited by
- 623
- References
- 17
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 20 · 2023: 18 · 2022: 28 · 2021: 35 · 2020: 28 · 2019: 23 · 2018: 25 · 2017: 37 · 2016: 42 · 2015: 38 · 2014: 53 · 2013: 28 · 2012: 54
- FWCI
- 8.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- doxorubicin, polymeric micelles, supramolecular nanocarriers, maximum tolerated dose, dose-limiting toxicity, neutropenia, pharmacokinetics, solid tumors, metastatic pancreatic cancer, accelerated titration, recommended phase 2 dose, drug delivery
- MeSH terms
- Aged, Antineoplastic Agents, Doxorubicin, Drug Administration Schedule, Female, Humans, Male, Micelles, Middle Aged, Nausea, Neoplasms, Neutropenia, Peptides, Polyethylene Glycols, Vomiting, Maximum Tolerated Dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.